null

Monalizumab Biosimilar (Anti-NKG2A) Antibody (HDBS0085)

SKU:
HDBS0085
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Protein:
NKG2A
Reactivity:
Human
Host Species:
Chimeric Humanized
Isotype:
IgG4
€399

Description

system_update_altDatasheet

Monalizumab (Anti-NKG2A) Biosimilar Antibody (HDBS0085)

The Monalizumab Biosimilar Anti-NKG2A Antibody is a revolutionary product designed for research purposes related to NKG2A, a cell surface receptor known to regulate immune responses. This antibody, derived from innovative biosimilar technology, is highly specific and reactive with human samples, making it an invaluable tool for studies in immunology and cancer research.Through binding to the NKG2A protein, this antibody enables precise detection and analysis in various cell types, allowing researchers to gain insights into the role of NKG2A in immune regulation and its potential therapeutic implications.

With its ability to modulate immune responses, NKG2A has emerged as a promising target for investigating diseases such as cancer, autoimmune disorders, and viral infections.By utilizing the Monalizumab Biosimilar Anti-NKG2A Antibody in their research, scientists can advance their understanding of immune regulation mechanisms and explore new therapeutic strategies for addressing complex diseases. This cutting-edge product offers a novel approach to studying NKG2A and holds great potential for driving breakthroughs in the field of immunotherapy.